Trade AstraZeneca ^AZN

ByteDance's Favored Child Unveils the Capital Game of the AI Pharmaceutical Industry

AZN: Mixed Trial Outcomes And China Expansion Will Shape Future Perception

Promising Manufacturing Stocks To Follow Today - September 18th

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

AstraZeneca (AZN) Stock Gains Momentum Following CEO Share Purchase and European Drug Approval

AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III Success

AstraZeneca (AZN)'s Lung Drug Delivers the Good News its Pipeline Needed

Dallas-Based Susan G. Komen Teams with AstraZeneca to Broaden Navigation Services for Breast Cancer Patients

AstraZeneca (AZN) Wins FDA Approval for its Breast Cancer Pill After Regulators Voiced Doubts

AstraZeneca invests $30 million to upgrade production and supply base in China

Astrazeneca Plc (NYSE:AZN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

The West is hooked on Chinese drugs but they could save your life

Innate Pharma Reports First Half 2026 Business Update and Financial Results | Morningstar

NHS to offer life-extending breast cancer drug after pricing row

Astrazeneca (NYSE:AZN) Rating Lowered to Strong Sell at Zacks Research

AstraZeneca price target lowered to 150 GBp from 160 GBp at Berenberg

AstraZeneca (LON:AZN) Insider Acquires £303,025 in Stock

AstraZeneca's Oncology Engine Faces a Key Test After Camizestrant Miss

New Strong Sell Stocks for September 15th

Berenberg Bank Has Lowered Expectations for AstraZeneca (LON:AZN) Stock Price - Stock Observer

RBC Capital Sticks to Their Buy Rating for AstraZeneca (AZN)

Top Manufacturing Stocks Worth Watching - September 14th - Daily Political

Erste Group Bank Forecasts Stronger Earnings for Astrazeneca - Stock Observer

Beyond the breakthrough for RAS-driven cancers

Why the Market Dipped But Astrazeneca (AZN) Gained Today

AstraZeneca: Etcamah Fails a Phase 3 Metastatic Breast Cancer Trial | Morningstar

AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial | World News

Astrazeneca reports discovery of NNMT inhibitor for cardiorenal disease

Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results

Top Pharmaceutical Stocks To Research - September 14th - Daily Political

Dow Jones Top Company Headlines at 5 AM ET: Biggest AI Rivals Agree They Need to Slow It Down | AstraZeneca ... | Morningstar

AstraZeneca's TAGRISSO Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer

AstraZeneca's Enhertu Improves PFS By 6 Months In First-Line HER2-Mutant NSCLC; Daiichi Stock Up

AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective

Erste Group Bank Expects Stronger Earnings for Astrazeneca

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial | Morningstar

Olema selloff on AstraZeneca miss a buying opportunity, says Citi

Rheumatoid Arthritis Market Outlook 2036: Advancements in Biologics and Emerging Therapies to Drive Market Growth Across the 7MM | ABNewswire

Anti-GPC3 Targeted Therapies Market Poised for Growth Through 2040 as Expanding Patient Populations and Competitive Innovation Unlock New Opportunities | Valuespectrum.com

AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears - Daily Political

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

AstraZeneca's Etcamah Fails Key Breast Cancer Trial

AstraZeneca's breast cancer drug Etcamah fails to achieve primary goal

AstraZeneca down 2% at $157 after SERENA-4 trial update

AstraZeneca Says Breast Cancer Pill Fails in Key Study

Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN)

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca

Top Manufacturing Stocks To Research - September 11th - Stock Observer

Can a Tagrisso Combination Strengthen AstraZeneca's Path to $80 Billion? - Insider Monkey

Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors

AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche

Amgen (NASDAQ:AMGN) Shares Gap Down - What's Next? - Stock Observer

COPD Clinical Trial Pipeline Gains Momentum: 65+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | ABNewswire

Could AstraZeneca (AZN)'s Stronger Growth Make it a Better Bet than Amgen (AMGN)?

AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough

Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Meets Major Goals

Manufacturing Stocks Worth Watching - September 9th - Stock Observer

Cidel Asset Management Inc. Takes Position in Astrazeneca Plc $AZN

Stock Analysts' Updated EPS Estimates for September 9th (AZN, BBOT, BBOX, BEAM, BRZE, CASY, COA, CRE, DNLM, DYN) - Daily Political

AstraZeneca (LON:AZN) Earns "Buy" Rating from Jefferies Financial Group - Markets Daily

AstraZeneca (LON:AZN) Earns Outperform Rating from Royal Bank Of Canada - Daily Political

Amgen and AstraZeneca Reveal Promising Lung Cancer Drug Combination That Enhances Survival Rates, ETPharma

AstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - Daily Political

RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial

AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test

FDA clears Astrazeneca's Etcamah for first-line breast cancer

Amgen And AstraZeneca's IMDELLTRA-Imfinzi Combo Shows Survival Benefit In Phase 3 ES-SCLC Study

AstraZeneca Reports Positive Data For Tozorakimab From Phase III OBERON, TITANIA Trials In COPD

Correction to AstraZeneca Article | Morningstar

AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups | Morningstar

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

Top Manufacturing Stocks To Watch Today - September 8th - Daily Political

IMFINZI® plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer | INN

AstraZeneca's Etcamah Approved In U.S. For 1st-Line Advanced HR-Positive Breast Cancer

Astrazeneca Plc $AZN Shares Sold by HighTower Advisors LLC

Commercial Assessment of the Diabetic Nephropathy Market 2026-2036 Featuring Boehringer Ingelheim, Eli Lilly, Bayer, AstraZeneca, UCB Biopharma, Serodus, and Palatin

Astrazeneca Plc $AZN Shares Bought by Allianz Asset Management GmbH

Dilated Cardiomyopathy Clinical Trial Pipeline Gains Momentum: 8+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | ABNewswire

AstraZeneca India Launches Rs 25 Lakh Cancer Cover for Employees, ETHRWorld

J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)

Astrazeneca Plc $AZN Shares Sold by Groupe la Francaise

Amundi Purchases 1,036,635 Shares of Astrazeneca Plc $AZN

AstraZeneca Announces Approval Of Etcamah Combination In The US

Citi Keeps Their Buy Rating on AstraZeneca (AZN)

FDA Approves Guardant360 CDx Companion Diagnostic For ESR1-Mutated Breast Cancer

AstraZeneca's (AZN) Buy Rating Reiterated at Berenberg Bank - Stock Observer

Best Manufacturing Stocks To Follow Today - September 5th

Haleon And 2 British AI Healthcare Stocks To Watch

US FDA approves AstraZeneca's new breast cancer pill Etcamah: Dosage, high risk and side effects - All you need to know

Dollar to Mexican Peso Forecast 2026–2030: Can USD/MXN Break Above 17.50 as the Rate Gap Narrows?

Avalanche Price Prediction 2026–2030: Can Institutional Tokenization Push AVAX Back Above $10?

Week Ahead: PBoC and SNB rate decisions

Gold Price Forecast 2026, 2027 and 2030: Can Gold Hold $4,200 After the Fed’s First Rate Hike Since 2023?

Fed Interest Rate Forecast 2026: Will the Fed Raise Rates Again?

Is SpaceX a Good Stock to Buy in 2026?

Best Gold Stock to Buy Now: 6 Gold Stocks to Watch in 2026

Advanced CFD Trading Tools Review: Which Tools Can Improve Your Trading Decisions?

Gold Price Trend 2024-2026: From $2,000 to Record Highs, What Comes Next?

Upcoming IPOs 2026: The Biggest Companies to Watch and Major Listings So Far

SpaceX Nasdaq-100 Weight More Than Doubles, Setting Up Billions in Passive Buying

Gold Price Today: Gold Edges Lower Near $4,372 as Fed Rate Outlook Keeps Yields Elevated

Bitcoin Surges Toward $84,000 on SEC Relief and ETF Inflows

Gold Price Forecast This Week: Can XAU/USD Hold $4,350 as Fed Speakers Turn Hawkish?

SoftBank Raises Over $11 Billion for OpenAI: What the Bond Deal Means for the Stock

US PMI Preview: Will Strong Business Activity Push the 10-Year Treasury Yield Back Above 5%?

Nvidia CEO Jensen Huang Rejects AI Slowdown Calls as Industry Divide Deepens

Trump-Xi Meeting Preview: Can an AI Deal and Tariff Relief Lift Global Markets?